▶ 調査レポート

等温核酸増幅技術(INAAT)のグローバル市場(~2027):アッセイ・キット・試薬、システム

• 英文タイトル:Isothermal Nucleic Acid Amplification Technology/INAAT Market Research Report by Product, Technology, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Isothermal Nucleic Acid Amplification Technology/INAAT Market Research Report by Product, Technology, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「等温核酸増幅技術(INAAT)のグローバル市場(~2027):アッセイ・キット・試薬、システム」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2304J0202
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、246ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:バイオ
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の本調査資料によると、世界の等温核酸増幅技術(INAAT)市場規模は、2021年2,115.06百万ドルから2022年に2,393.83百万ドルへと拡大、その後2027年までに年平均13.43%成長して4,506.14百万ドルに達する見通しです。本書は、等温核酸増幅技術(INAAT)の世界市場を対象とした調査・分析結果を整理したものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析(アッセイ・キット・試薬、システム)、技術別分析(ヘリカーゼ依存増幅、ループ媒介等温増幅、核酸配列ベース増幅、ストランド変位増幅、転写媒介増幅)、用途別分析(血液スクリーニング、感染症診断)、エンドユーザー別分析(学術&研究機関、病院、リファレンスラボラトリー)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの項目を掲載しています。なお、本書には、Abbott Laboratories, Inc.、Becton, Dickinson And Company、Biomérieux Sa、Diasorin Group S.P.A、Eiken Chemicals Co., Ltd.、Ge Healthcare、Genomtec Sa、Grifols, S.A.、Hologic, Inc.、Illumina, Inc.、Lucigen Corporationなどの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の等温核酸増幅技術(INAAT)市場規模:製品別
- アッセイ・キット・試薬の市場規模
- システムの市場規模
・世界の等温核酸増幅技術(INAAT)市場規模:技術別
- ヘリカーゼ依存増幅の市場規模
- ループ媒介等温増幅の市場規模
- 核酸配列ベース増幅の市場規模
- ストランド変位増幅の市場規模
- 転写媒介増幅の市場規模
・世界の等温核酸増幅技術(INAAT)市場規模:用途別
- 血液スクリーニングにおける市場規模
- 感染症診断における市場規模
・世界の等温核酸増幅技術(INAAT)市場規模:エンドユーザー別
- 学術&研究機関における市場規模
- 病院における市場規模
- リファレンスラボラトリーにおける市場規模
・世界の等温核酸増幅技術(INAAT)市場規模:地域別
- 南北アメリカの等温核酸増幅技術(INAAT)市場規模
アメリカの等温核酸増幅技術(INAAT)市場規模
カナダの等温核酸増幅技術(INAAT)市場規模
ブラジルの等温核酸増幅技術(INAAT)市場規模
...
- アジア太平洋の等温核酸増幅技術(INAAT)市場規模
日本の等温核酸増幅技術(INAAT)市場規模
中国の等温核酸増幅技術(INAAT)市場規模
インドの等温核酸増幅技術(INAAT)市場規模
韓国の等温核酸増幅技術(INAAT)市場規模
台湾の等温核酸増幅技術(INAAT)市場規模
...
- ヨーロッパ/中東/アフリカの等温核酸増幅技術(INAAT)市場規模
イギリスの等温核酸増幅技術(INAAT)市場規模
ドイツの等温核酸増幅技術(INAAT)市場規模
フランスの等温核酸増幅技術(INAAT)市場規模
ロシアの等温核酸増幅技術(INAAT)市場規模
...
- その他地域の等温核酸増幅技術(INAAT)市場規模
・競争状況
・企業情報

The Global Isothermal Nucleic Acid Amplification Technology/INAAT Market size was estimated at USD 2,115.06 million in 2021 and expected to reach USD 2,393.83 million in 2022, and is projected to grow at a CAGR 13.43% to reach USD 4,506.14 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Isothermal Nucleic Acid Amplification Technology/INAAT to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Assays, Kits, And Reagents and Systems.

Based on Technology, the market was studied across Helicase-dependent Amplification, Loop-mediated Isothermal Amplification, Nucleic Acid Sequence-based Amplification, Strand Displacement Amplification, and Transcription-mediated Amplification.

Based on Application, the market was studied across Blood Screening and Infectious Disease Diagnosis. The Infectious Disease Diagnosis is further studied across Ct/Ng, Hepatitis, HIV, and Influenza.

Based on End User, the market was studied across Academic & Research Institutes, Hospitals, and Reference Laboratories.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Isothermal Nucleic Acid Amplification Technology/INAAT market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Isothermal Nucleic Acid Amplification Technology/INAAT Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market, including Abbott Laboratories, Inc., Becton, Dickinson And Company, Biomérieux Sa, Diasorin Group S.P.A, Eiken Chemicals Co., Ltd., Ge Healthcare, Genomtec Sa, Grifols, S.A., Hologic, Inc., Illumina, Inc., Lucigen Corporation, Mast Group Ltd., Meridian Bioscience, New England Biolabs, Inc., Qiagen, Quidel Corporation, Tecan Trading Ag, Thermo Fisher Scientific, Inc., Twistdx Limited, and Ustar Biotechnologies Ltd..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market?
4. What is the competitive strategic window for opportunities in the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market?
5. What are the technology trends and regulatory frameworks in the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market?
6. What is the market share of the leading vendors in the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market?
7. What modes and strategic moves are considered suitable for entering the Global Isothermal Nucleic Acid Amplification Technology/INAAT Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for INAAT and the rising prevalence of infectious diseases
5.1.1.2. Increase in the adoption of INAAT over other molecular diagnostic techniques like PCR
5.1.1.3. Rising approvals from healthcare regulatory authorities for innovative technologies
5.1.2. Restraints
5.1.2.1. Lack of awareness about the advanced diagnostics methods
5.1.3. Opportunities
5.1.3.1. Developing miniaturization of nucleic acid-based diagnostics
5.1.3.2. Extensive R&D for INAAT in the detection of cancer-specific molecular biomarkers
5.1.4. Challenges
5.1.4.1. Stringent regulatory framework
5.2. Cumulative Impact of COVID-19

6. Isothermal Nucleic Acid Amplification Technology/INAAT Market, by Product
6.1. Introduction
6.2. Assays, Kits, And Reagents
6.3. Systems

7. Isothermal Nucleic Acid Amplification Technology/INAAT Market, by Technology
7.1. Introduction
7.2. Helicase-dependent Amplification
7.3. Loop-mediated Isothermal Amplification
7.4. Nucleic Acid Sequence-based Amplification
7.5. Strand Displacement Amplification
7.6. Transcription-mediated Amplification

8. Isothermal Nucleic Acid Amplification Technology/INAAT Market, by Application
8.1. Introduction
8.2. Blood Screening
8.3. Infectious Disease Diagnosis
8.4.1. Ct/Ng
8.4.2. Hepatitis
8.4.3. HIV
8.4.4. Influenza

9. Isothermal Nucleic Acid Amplification Technology/INAAT Market, by End User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Hospitals
9.4. Reference Laboratories

10. Americas Isothermal Nucleic Acid Amplification Technology/INAAT Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Isothermal Nucleic Acid Amplification Technology/INAAT Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Isothermal Nucleic Acid Amplification Technology/INAAT Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Abbott Laboratories, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Becton, Dickinson And Company
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Biomérieux Sa
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Diasorin Group S.P.A
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Eiken Chemicals Co., Ltd.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Ge Healthcare
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Genomtec Sa
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Grifols, S.A.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Hologic, Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Illumina, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Lucigen Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Mast Group Ltd.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Meridian Bioscience
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. New England Biolabs, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Qiagen
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Quidel Corporation
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Tecan Trading Ag
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Thermo Fisher Scientific, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Twistdx Limited
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Ustar Biotechnologies Ltd.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing